P. Björk

2.6k total citations · 1 hit paper
51 papers, 2.1k citations indexed

About

P. Björk is a scholar working on Immunology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, P. Björk has authored 51 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Immunology, 12 papers in Pulmonary and Respiratory Medicine and 10 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in P. Björk's work include Prostate Cancer Treatment and Research (7 papers), Radiopharmaceutical Chemistry and Applications (5 papers) and Blood Coagulation and Thrombosis Mechanisms (5 papers). P. Björk is often cited by papers focused on Prostate Cancer Treatment and Research (7 papers), Radiopharmaceutical Chemistry and Applications (5 papers) and Blood Coagulation and Thrombosis Mechanisms (5 papers). P. Björk collaborates with scholars based in Sweden, Denmark and United States. P. Björk's co-authors include K. Ohlsson, Magnus Bergenfeldt, Robert Hageman, Robert C. Thompson, Mikael Dohlsten, Per Nilsson, Tommy Knöös, Lars Abrahmsén, Terje Kalland and Hans Rorsman and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

P. Björk

51 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Interleukin-1 receptor antagonist reduces mortality from endotoxin shock

1990 658 citations K. Ohlsson, P. Björk et al. profile →

Peers

Countries citing papers authored by P. Björk

Since Specialization

Citations

This map shows the geographic impact of P. Björk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Björk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Björk more than expected).

Fields of papers citing papers by P. Björk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Björk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Björk. The network helps show where P. Björk may publish in the future.

Co-authorship network of co-authors of P. Björk

This figure shows the co-authorship network connecting the top 25 collaborators of P. Björk. A scholar is included among the top collaborators of P. Björk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Björk. P. Björk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Trichoderma harzianum Peptaibols Stimulate Plant Plasma Membrane H⁺-ATPase Activity 2023 ·ACS Omega ·P. Björk, Nicolai Tidemand Johansen, (unknown), Silas Anselm Rasmussen, Johan Ø. Ipsen, Thomas Isbrandt, Thomas Ostenfeld Larsen, Anja T. Fuglsang	4
2	Tenuazonic acid from Stemphylium loti inhibits the plant plasma membrane H⁺‐ATPase by a mechanism involving the C‐terminal regulatory domain 2019 ·New Phytologist ·P. Björk, Silas Anselm Rasmussen, (unknown), (unknown), Thomas Isbrandt, Johan Ø. Ipsen, Thomas Ostenfeld Larsen, Anja T. Fuglsang	27
3	Clinical‐scale generation of strongly CD83‐expressing dendritic cells using extracorporeal photopheresis 2007 ·Photodermatology Photoimmunology & Photomedicine ·Anders Bredberg, (unknown), Anders Lindblom, P. Björk	3
4	ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura 2006 ·European Journal of Pediatrics ·(unknown), Ann‐Charlotte Kristoffersson, Han‐Mou Tsai, Wenhua Zhou, Ingemar Winqvist, Göran Oldæus, Rolf Billström, P. Björk, Lars Holmberg, Diana Karpman	25
5	Dosimetry characteristics of degraded electron beams investigated by Monte Carlo calculations in a setup for intraoperative radiation therapy 2002 ·Physics in Medicine and Biology ·P. Björk, Per Nilsson, Tommy Knöös	23
6	Aberrant Expression of the CD8 Antigen in B Cell Chronic Lymphocytic Leukaemia 2002 ·Leukemia & lymphoma ·(unknown), P. Björk, Karin Magnussen, Torolf Moen, (unknown)	11
7	Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen 2001 ·British Journal of Cancer ·G. Forsberg, Lennart Ohlsson, Thomas Brodin, P. Björk, Peter A. Lando, Duncan Shaw, P L Stern, Mikael Dohlsten	54
8	Design and dosimetry characteristics of a soft-docking system for intraoperative radiation therapy 2000 ·International Journal of Radiation OncologyBiologyPhysics ·P. Björk, Tommy Knöös, Per Nilsson, (unknown)	16
9	Comparative dosimetry of diode and diamond detectors in electron beams for intraoperative radiation therapy 2000 ·Medical Physics ·P. Björk, Tommy Knöös, Per Nilsson	42
10	The macrophage migration inhibitory factor MIF is a phenylpyruvate tautomerase 1997 ·FEBS Letters ·Evald Rosengren, Pierre Åman, (unknown), Christer Hansson, (unknown), P. Björk, Lars Jacobsson, Hans Rorsman	213
11	α₂‐macroglobulin and α₁‐inhibitor‐3 mRNA expression in the rat liver after slow interleukin‐1 stimulation 1996 ·Mediators of Inflammation ·(unknown), P. Björk, K. Ohlsson	1
12	Estramustine-binding protein and specific binding of the anti-mitotic compound estramustine in astrocytoma. 1994 ·PubMed ·A. Tommy Bergenheim, P. Björk, Jonas Bergh, E. von Schoultz, (unknown), Roger Henriksson	19
13	Evidence for a non‐estrogenic cytostatic effect of estramustine on human prostatic carcinoma cells in vivo 1992 ·The Prostate ·(unknown), Sten Nilsson, (unknown), P. Björk, Beryl Hartley‐Asp	35
14	Release of Dog Polymorphonuclear Leukocyte Cathepsin G, Normally and in Endotoxin and Pancreatitic Shock. Isolation and Partial Characterization of Dog Polymorphonuclear Leukocyte Cathepsin G 1991 ·Biological Chemistry Hoppe-Seyler ·P. Björk, Lena Axelsson, (unknown)	11
15	Release of immunoreactive canine leukocyte elastase normally and in endotoxin and pancreatitic shock 1990 ·Scandinavian Journal of Clinical and Laboratory Investigation ·Lena Axelsson, Magnus Bergenfeldt, P. Björk, Rolf Olsson, K. Ohlsson	9
16	Purification and N-Terminal Amino-Acid Sequence Analysis of Rat Polymorphonuclear Leukocyte Cathepsin G 1990 ·Biological Chemistry Hoppe-Seyler ·P. Björk, K. Ohlsson	10
17	Local Administration of Human Pancreatic Secretory Trypsin Inhibitor Prevents the Development of Experimental Acute Pancreatitis in Rats and Dogs 1989 ·Scandinavian Journal of Gastroenterology ·K. Ohlsson, Rolf Olsson, P. Björk, G Balldin, A. Borgström, Å. Lasson, Tadashi Kohno, R. C. Thompson	21
18	Functional Studies of Human Secretory Leukocyte Protease Inhibitor 1988 ·Advances in experimental medicine and biology ·K. Ohlsson, Magnus Bergenfeldt, P. Björk	18
19	Metabolites of estramustine in human pancreatic cancer 1986 ·Digestion ·A.A. Sandberg, (unknown), P. Björk, Per Olov Gunnarsson	2
20	The interaction of steroidal alkylating agents with binding components in the soluble fraction of the prostate. 1979 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·B. Högberg, P. Björk, Kjell Carlström, Björn Forsgren, Jan-Ακε Gustafsson, T. Hökfelt, Åke Pousette	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact